Building future
worth through data
Creating future worth through data.
worth through data
Total 23 Posts
-
Received the $3 Million Export TrophyDaehan New Pharm received the $3 Million Export Trophy at the 42nd Trade Day event held on the 31st. This achievement came 7 years after the company's first export to Vietnam in 1999 and 3 years after receiving the $1 Million Export Trophy in 2002. Daehan New Pharm exports primarily cephalosporin pharmaceuticals to over 20 countries including Vietnam, Pakistan, and Cuba. Recently, exports of thrombolytic agent streptokinase and anticancer drugs have also significantly increased, and this year the company entered the pharmaceutical markets in Azerbaijan and Nigeria. A company spokesperson said, 'Receiving the $3 Million Export Trophy signifies that the excellence in quality has been highly recognized overseas,' and added, 'We will continue to strive to achieve $5 million and $10 million export milestones.' Daehan New Pharm plans to maintain continuous efforts towards export growth by expanding overseas partnerships and fostering export strategies for marketable products.Source: Money Today, Reporter Choi Jeong-ho2005.12.01 -
Medical Supplies Support to Iraq Zaytun UnitOn the 28th, Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) announced that it had delivered medical supplies valued at approximately 15 million KRW to the Zaytun Unit deployed in Iraq. Brigade Commander Lim Guk-sun of the Zaytun Unit expressed gratitude for the support and stated, "The medical supplies will mainly be used for civil service activities in about 20 villages in the area where the unit is stationed in Iraq."2005.11.30 -
[Notice] Instructions for Changes to Approval Details (November 18, 2005)[Notice] Based on the Ministry of Food and Drug Safety Pharmaceutical Management Team-12079 (’05.11.18), the unified adjustment plan regarding the approval details (precautions for use) for fluoxetine hydrochloride single formulation (oral) and, based on the Ministry of Food and Drug Safety Narcotics Management Team-15069 (’05.11.18), the unified adjustment plan regarding approval details (indications, dosage and administration, precautions for use) for psychotropic anorectic agent phentermine hydrochloride formulation are as follows. Affected products include:Depren Capsules (Fluoxetine Hydrochloride)Melcapt Tablets (Mercaptopurine)Festy Tablets (Phentermine Hydrochloride) For inquiries related to this notice: Responsible Department: Daehan New Pharm Development Division Contact: 02-3415-78572005.11.28 -
Daehan New Pharm 21st Anniversary CelebrationOn the 20th, Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) held a celebration at the company’s main auditorium with all employees in attendance to mark its 21st anniversary. The event included an awards ceremony for six employees with 20 and 10 years of long-term service, a congratulatory speech, and a ceremonial rice cake cutting. Chairman Lee Wan-jin, in his address, emphasized the company’s dignity and pride as it reached adulthood in the 21st century and urged the completion of mid- to long-term development plans to achieve the greatest accomplishments in company history. He laid out key future management directives for creating a new future: (1) focusing core competencies on profitability improvement, (2) elevating all employees’ energy into a growth engine, and (3) dedicating efforts to self-development and R&D. He also expressed hope that the anniversary celebration would be a meaningful occasion for all employees to renew their commitment to transformation and leap-forward growth. During the event, Assistant Manager Yoon Young-sun of the Factory Management Team was awarded for 20 years of service and received a prize of 20 don of gold, while Assistant Manager Oh Seok-gyun of the Bio Team and four others received 10-year service awards with 10 don of gold. In addition, 33 outstanding employees were granted overseas training opportunities in Southeast Asia as awards.2005.10.20 -
ATAT 2005 Achievement Seminar and Hiking CompetitionDaehan New Pharm Practices 'V-3 UP' for Achieving GoalsSix-Hour Climb to Biro Peak on Odaesan Mountain... Awards Ceremony for 33 Outstanding Employees Held Daehan New Pharm (CEO Park Myung-rae) held the 'ATAT 2005 (Achieving Target All Together)' seminar and hiking event over two days on the 7th and 8th, with all employees participating to strengthen commitment to goal achievement, establish goal awareness, and activate sales. On the first day, the hike course started from Sangwonsa Temple on Odaesan Mountain and circled Biro Peak, with everyone completing the approximately 6-hour journey without incident. The evening gathering fostered team unity and was a lively affirmation of organizational strength. On the second day, an in-depth discussion on the strategies of each business unit for achieving goals in the second half of 2005 was held during the 'ATAT 2005 Achievement Seminar' aimed at leaping forward as a top-tier company. Based on the slogan "Let's Achieve Our Goals Together," the detailed execution goals of 'V-3 UP' (Volume up: achieving goals, Value up: creating value, Vision up: creating the future) were set to strengthen unity among all employees. This marked a spirited leap toward successful completion of 2005 and a fresh start for 2006. The event also included an awards ceremony for 33 outstanding employees, granted overseas training opportunities in Southeast Asia, and a special lecture titled "The Difference Between Professionals and Amateurs" delivered by lightning courier instructor Jo Tae-hoon emphasizing professional spirit.2005.10.10 -
[Notice] 2004 Pharmaceutical Reevaluation ResultsIn accordance with Article 26-3 and Article 34, Paragraph 4 of the Pharmaceutical Affairs Act and [Regulations on the Implementation of Drug Reevaluation (KFDA Notification)], reevaluation was conducted on [2 therapeutic groups of artificial perfusion agents, 22 sites, 141 items] and [4 other metabolic therapeutic groups, 55 sites, 848 items], and the results are hereby announced. Affected products include:Glizide Tablets (Gliclazide)Daien Capsules (Green Tea Powder, Ortho-Ciphen Powder)Bronase Tablets (Deoxyribonuclease, Bromelain) For inquiries related to this announcement: Responsible Department: Daehan New Pharm Development Division Contact: 02-3415-78572005.06.30 -
Launch of Sancotec Tablet, an AntihistamineDaehan New Pharm Co., Ltd. has newly launched the OTC packaging of Sancotec Tablet, a second-generation antihistamine tablet. The Sancotec Tablet (10T) is available for purchase at pharmacies and contains cetirizine hydrochloride, a widely used anti-allergic agent worldwide. It works by blocking histamine receptors and is highly effective for symptoms such as allergic rhinitis, allergic conjunctivitis, urticaria, and itching of the skin. The drug is rapidly absorbed for quick onset of effect and provides 24-hour efficacy with a simple once-daily one-tablet dose. As a second-generation antihistamine, it significantly reduces side effects like drowsiness and sedation. Itively targets H1 receptors without anticholinergic or antiserotonin effects, making it a safe formulation suitable for children aged 6 and above. For inquiries: Academic Development Department 02-3415-78392005.05.17 -
Daehan New Pharm Co., Ltd. to Hold Regular General Meeting of Shareholders on the 18thDaehan New Pharm Co., Ltd. held the 21st Regular General Meeting of Shareholders on the 18th at the Hyangnam Pharmaceutical Complex in Hyangnam-myeon, Hwaseong-si, Gyeonggi-do. At the meeting, a cash dividend of 50 KRW (10%) was approved. Additionally, attorney Cho Yeon-ho was appointed as a new outside director, succeeding Dr. Yang Ji-won, who stepped down due to personal reasons. Daehan New Pharm's sales for 2004 reached 42.182 billion KRW, marking a strong growth of 17.4% compared to the previous year. Operating profit increased by 30.7% to 2.569 billion KRW due to sales growth, and ordinary profit rose by 5.7% to 1.463 billion KRW. However, net income for the year decreased by 8.4% to 904.8 million KRW due to an increase in deferred corporate taxes. CEO Park Myung-rae stated, "Daehan New Pharm will continue to maximize sales performance through continuous new product development and proactive customer-centered sales and marketing activities this year. We will also strengthen the accuracy and speed of operations by stabilizing the ERP system, making this year the first year for preparing to enter the 100 billion KRW sales era."2005.03.18 -
Daehan New Pharm is conducting mass recruitment of new employeesDaehan New Pharm Co., Ltd. has launched an intensive 18-day residential training program starting on the 26th, following the large-scale recruitment of new employees to strengthen their marketing, sales, and overseas business departments. Around 30 new and experienced employees,ed through document screening and interviews, including candidates for specialized task forces focusing on strategic product development, began the training at the Blue Monte Training Center in Anyang, Gyeonggi Province. The rigorous training schedule runs daily from 8:00 AM to 9:00 PM and covers basic pharmaceutical environment education, product knowledge, academic studies, and sales techniques. CEO Park Myung-rae, in his opening speech, emphasized that the company's future depends on the correct judgment and proactive actions of the new employees and urged them to devote themselves to the training with strong determination to become key players in self-realization and the company's leap to a top-tier organization.2005.01.26


Home